[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 2006

Determining the Value of Surgical Therapies for Basal Cell Carcinoma

Arch Dermatol. 2006;142(2):231-232. doi:10.1001/archderm.142.2.231

Structured literature reviews have concluded that scientific evidence is insufficient to recommend a single treatment as superior for most basal cell carcinomas (BCCs).1,2 Nonetheless, the conviction that Mohs micrographic surgery (MMS) is the best therapy is widespread. A recent editorial raised several questions about the advisability of a randomized trial of BCC treatments, stating “The evidence strongly suggests, as does common sense, that MMS is more effective at eradicating a given primary BCC than is surgical excision.”3(p1257)

First Page Preview View Large
First page PDF preview
First page PDF preview